Indivior (INDV) Projected to Post Quarterly Earnings on Thursday

Indivior (NASDAQ:INDV) is expected to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.65 per share and revenue of $305.62 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Indivior Stock Down 1.1%

INDV stock opened at $34.36 on Thursday. Indivior has a 52-week low of $7.62 and a 52-week high of $38.00. The firm has a market cap of $4.30 billion, a P/E ratio of 37.35 and a beta of 0.80. The company’s 50-day simple moving average is $34.84 and its 200-day simple moving average is $29.48.

Insiders Place Their Bets

In related news, Director Mark Stejbach acquired 775 shares of Indivior stock in a transaction that occurred on Monday, January 5th. The shares were purchased at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the transaction, the director owned 16,847 shares in the company, valued at $596,215.33. This represents a 4.82% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Barbara Ryan acquired 775 shares of the stock in a transaction on Monday, January 5th. The shares were bought at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the purchase, the director directly owned 1,963 shares of the company’s stock, valued at $69,470.57. The trade was a 65.24% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders bought 4,871 shares of company stock worth $172,385.

Institutional Investors Weigh In On Indivior

A number of institutional investors have recently modified their holdings of INDV. Virtus Advisers LLC acquired a new stake in shares of Indivior in the 4th quarter valued at approximately $215,000. Rafferty Asset Management LLC purchased a new stake in shares of Indivior in the fourth quarter valued at about $237,000. CIBC Private Wealth Group LLC purchased a new position in Indivior during the fourth quarter worth $216,000. Cerity Partners LLC acquired a new position in Indivior in the 4th quarter valued at about $229,000. Finally, Polymer Capital Management US LLC purchased a new position in shares of Indivior during the third quarter valued at approximately $238,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on INDV shares. Zacks Research lowered Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. Northland Securities set a $50.00 price target on shares of Indivior in a research note on Tuesday, January 20th. Piper Sandler restated an “overweight” rating and set a $41.00 price objective (up from $27.00) on shares of Indivior in a research report on Friday, October 31st. Morgan Stanley reiterated an “overweight” rating and issued a $36.00 target price on shares of Indivior in a research report on Wednesday, December 3rd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Indivior in a research note on Wednesday, January 28th. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $39.33.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.